Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

• Main Authors: Samia Shabnaz (Author), Trang N. Nguyen (Author), Roy Williams (Author), Samuel M. Rubinstein (Author), Timothy J. Garrett (Author), Marwa Tantawy (Author), Michael G. Fradley (Author), Mohammed E. Alomar (Author), Kenneth H. Shain (Author), Rachid C. Baz (Author), Daniel Lenihan (Author), Robert F. Cornell (Author), Qing Lu (Author), Yan Gong (Author)
• Format: Book
• Published: Wiley, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify those at high risk prior to carfilzomi...